Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06456892
Other study ID # Pucotenlimab-01
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 6, 2024
Est. completion date December 6, 2026

Study information

Verified date June 2024
Source Sun Yat-sen University
Contact Yizhuo Zhang
Phone 020-87342460
Email zhangyzh@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study comprises both Phase I and Phase II research. This phase focuses on safety, tolerability, and pharmacokinetics using a "3+3" dose escalation design with three dose groups: 1 mg/kg, 3 mg/kg, and 6 mg/kg. The drug will be administered in combination with the standard regimen for intermediate/high-risk rhabdomyosarcoma once every three weeks (Q3W). In phase II study, all subjects will receive Pucotenlimab combined with the standard regimen for intermediate/high-risk rhabdomyosarcoma for 2-4 cycles of neoadjuvant therapy every 3 weeks (Q3W), followed by surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 82
Est. completion date December 6, 2026
Est. primary completion date June 6, 2026
Accepts healthy volunteers No
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria: 1. Age: 1-18 years old; 2. ECOG PS score: 0-1 points; 3. Pathologically confirmed newly diagnosed children or adolescents with intermediate to high-risk rhabdomyosarcoma; 4. Patients evaluated by surgery as having a high degree of difficulty; 5. Must have at least one measurable lesion defined by RECIST or WHO criteria; 6. Expected survival time = 6 months; 7. Cardiac function: 1. Echocardiography shows LVEF = 50%; 2. EKG indicates no evidence of myocardial ischemia; 3. No history of arrhythmia requiring pharmacological intervention before enrollment; 8. No history of severe immune-related adverse events (CTCAE V4.03 G3 or G4); 9. For patients with known non-involvement of the bone marrow (BM): 1. Absolute neutrophil count (ANC) = 1.0 × 109/L; 2. Platelet count = 100.0 × 109/L; 3. Hemoglobin = 90 g/L; 10. Liver and kidney functions need to meet the following criteria: 1. Total bilirubin (conjugated + unconjugated) = 2.5 × upper limit of normal (ULN) corresponding to age, patients with confirmed Gilbert's syndrome may be enrolled based on the investigator's discretion; 2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 × ULN; 3. Estimated glomerular filtration rate = 30 mL/min/1.73 m2 or serum creatinine (Cr) = 1.5 × ULN; 11. Able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during the study; 12. The parents/guardians of the child or adolescent participants have the ability to understand, consent to, and sign the informed consent form (ICF) and applicable child consent forms before initiating any protocol-related procedures; the participants have the ability to express their consent (if applicable) with the consent of their parents/guardians. Exclusion Criteria: 1. Received anti-PD-1 or anti-PD-L1 monoclonal antibodies or targeted drugs related to these pathways; 2. Received chemotherapy, radiotherapy, or other treatments; 3. Previous surgical treatment (excluding biopsy); 4. Known allergy to PD-1 monoclonal antibodies or any of their excipients; known history of allergic diseases or severe allergies; 5. Having other malignant tumor diseases besides the tumor being treated in this study, excluding: malignant tumors that have been cured and have not recurred within 3 years before enrollment, completely resected basal cell and squamous cell skin cancers, completely resected carcinoma in situ of any type; 6. Active central nervous system metastases (whether treated or not), including symptomatic brain metastases, meningeal metastases, or spinal cord compression, etc. Excluding: asymptomatic brain metastases without progression within at least 4 weeks after radiotherapy and/or without neurological symptoms or signs after surgical resection, without the need for dexamethasone or mannitol treatment. 7. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; 8. Previous treatment toxicity still > Grade 1 (CTCAE V4.03 criteria), excluding alopecia and neurotoxicity; 9. History of mental disorders; 10. History of drug abuse or substance abuse upon inquiry; 11. History of idiopathic pulmonary fibrosis or idiopathic pneumonitis; 12. Comorbidities requiring immunosuppressive drug treatment, or comorbidities requiring systemic or local use of corticosteroids at immunosuppressive doses (prednisone > 10 mg/day or equivalent doses of similar drugs). 13. History of autoimmune diseases, including but not limited to systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis, etc. Excluding: Type I diabetes, hypothyroidism controllable only through hormone replacement therapy, dermatological diseases that do not require systemic treatment (such as vitiligo, psoriasis), controlled celiac disease, or diseases that are not expected to recur without external stimuli; 14. Previous or current active tuberculosis infection; 15. Active infections requiring systemic treatment; 16. Uncontrolled hypertension (systolic blood pressure = 140 mmHg and/or diastolic blood pressure = 90 mmHg) or pulmonary hypertension or unstable angina pectoris; myocardial infarction or bypass surgery, stenting within 6 months before administration; history of chronic heart failure satisfying New York Heart Association (NYHA) Class 3-4; clinically significant valvular heart disease; severe arrhythmias requiring treatment (excluding atrial fibrillation, paroxysmal supraventricular tachycardia), including QTc interval = 450 ms for males and = 470 ms for females (calculated using the Fridericia formula); cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months before administration; 17. Concurrent severe medical conditions, including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc.; 18. Positive Anti-HIV, TP-Ab, HCV-Ab; HBV-Ag positive with HBV DNA copy number > upper limit of normal value of the testing unit; 19. Abnormal thyroid function test results (FT3, FT4, T3, T4); 20. Expected to receive live or attenuated vaccines within 4 weeks before administration, during treatment, or within 5 months after the last dose; 21. Participated in another clinical trial and received experimental drug treatment within 30 days before administration;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pucotenlimab
Pucotenlimab Combined with Standard Chemotherapy Regimen

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary DLT dose-limiting toxicity within 28 days of the dose escalation phase.
Primary pCR pathological complete response rate from treatment of pucotenlimab to the surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Not yet recruiting NCT06335745 - PediCARE Health Equity Intervention in High-Risk Neuroblastoma N/A
Withdrawn NCT04719416 - Relaxation Therapy in Pediatric Oncology N/A
Completed NCT01645436 - Physical Activity in Pediatric Cancer (PAPEC) N/A
Completed NCT04409301 - Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation N/A
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting NCT05425043 - Granulocyte Transfusions After Umbilical Cord Blood Transplant N/A
Recruiting NCT05071859 - Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
Recruiting NCT03241251 - Screening for Psychosocial Risk in Flemish Families of a Child With Cancer
Recruiting NCT05384288 - Response to Influenza Vaccination in Pediatric Oncology Patients
Completed NCT04586491 - The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients N/A
Recruiting NCT05569512 - Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Phase 1/Phase 2
Enrolling by invitation NCT05294380 - Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
Completed NCT02665819 - Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility. N/A
Completed NCT02675166 - Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
Not yet recruiting NCT05454163 - Post-radiotherapy Rhinosinusitis in Children
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Withdrawn NCT01828502 - Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer Phase 2
Completed NCT02032121 - Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors N/A
Completed NCT03964259 - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Phase 1